Lupin Ltd — M&A Activity 2024

Jun 5, 2024

==> picture [79 x 93] intentionally omitted <==

June 5, 2024

BSE Limited

Department of Corporate Services, P. J. Towers, Dalal Street, Mumbai Samachar Marg,

MUMBAI - 400 001.

 National Stock Exchange of India Ltd.,

Exchange Plaza, Bandra Kurla Complex, Bandra (East), MUMBAI - 400 051.

Dear Sir/Madam,

Sub: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘Listing Regulation’).

We are pleased to enclose a Press Release as regards completion of acquisition by Lupin Atlantis Holdings SA, Switzerland, wholly owned subsidiary of the Company, of two well-known brands, Aarane[TM] in Germany and Nalcrom[TM] in Canada and the Netherlands, along with the associated trademark rights, from Sanofi.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the Listing Regulations.

The above is for your information and dissemination.

Thanking you,

For LUPIN LIMITED

Rajvardhan Vishnu Satam

Digitally signed by Rajvardhan Vishnu Satam DN: c=IN, st=Maharashtra, 2.5.4.20=c19d8ef961d9fa59e973a093a4d3924b2532eb2f496ea7 e2abcf74700f5375b7, postalCode=400104, street=2404,SEJAL TOWER,SEJAL PARK,LINK ROAD,GOREGAON WEST,Mumbai,Motilal Nagar,Borivali,Mumbai Suburban, pseudonym=9a4b7cd219ea516ad56e6d651dcbbe5b, title=0191, serialNumber=df8ebe60a88c796663c738ea25bfa0b475d195f72 6cdb67a2ff09c4242771b2a, o=Personal, cn=Rajvardhan Vishnu Satam Date: 2024.06.05 11:20:36 +05'30'

R. V. SATAM COMPANY SECRETARY (ACS - 11973)

Encl: a/a

Registered Office: 3[rd] Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323. Corporate Identity Number: L24100MH1983PLC029442 www.lupin.com

www.lupin.com

Press Release

==> picture [68 x 70] intentionally omitted <==

BSE: 500257 NSE: LUPIN REUTERS: LUPIN.BO BLOOMBERG: LPC IN

Lupin Completes Acquisition of two Brands from Sanofi in Europe and Canada

Mumbai, June 05, 2024: Global pharma major Lupin Limited (Lupin) today announced that its European hub entity, Lupin Atlantis Holdings SA, has completed the acquisition of two well-known brands, Aarane[TM] in Germany and Nalcrom[TM] in Canada and the Netherlands, along with the associated trademark rights, from Sanofi.

The transaction aligns with Lupin's strategy to grow its global presence in Specialty areas, where the company has a leading position, with high-quality products that are innovative or unique in the market. This acquisition will enhance Lupin's Respiratory business in Germany, by aiding in the expansion of the newly established franchise, following the introduction of Luforbec[TM] .

About Nalcrom[TM]

Nalcrom[TM] (sodium cromoglicate Oral) belongs to a group of medicines called anti-allergics. It is used to treat food allergies after adequate testing for sensitivity to specific allergens in conjunction with restricting the main allergens.

About Aarane[TM]

Aarane[TM] (sodium cromoglicate/reproterol hydrochloride pressurized inhalation) is a chromone complex indicated in symptomatic acute treatment of sudden asthma attacks (e.g., allergic forms or those triggered by exertion, stress or infections) and targeted prevention of exercise-induced asthma or in cases of foreseeable allergen contact.

Dr. Fabrice Egros, President – Corporate Development, Lupin said, “This acquisition will strengthen

our global position in treating patients suffering from diverse respiratory diseases and conditions, and it adds accretive assets in gastro-intestinal care that broaden our portfolio of branded products. We are committed to provide our customers and patients with the best products and services in the market segments where we are present, improving the quality of life for millions of people around the world.”

About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 7.8% of its revenue in research and development in FY24.

Page 1 of 2

Press Release

==> picture [68 x 70] intentionally omitted <==

BSE: 500257 NSE: LUPIN REUTERS: LUPIN.BO BLOOMBERG: LPC IN

Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.

Please visit www.lupin.com for more information. Follow us on LinkedIn: https://www.linkedin.com/company/lupin Facebook: http://www.facebook.com/LupinWorld/ Twitter: https://twitter.com/LupinGlobal

About Sanofi

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.

For further information or queries, please contact –

Heena Dhedhi

Deputy General Manager – Corporate Communications Email: heenadhedhi@lupin.com

Page 2 of 2